Cell line · CVCL_1697
Papers45
1 to 20 of 45
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Pathogenic autoantibodies targeting DNA repair proteins are shared by cancer patients and healthy children later diagnosed with cancer. | Front Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Prognostic characteristics of disulfidptosis-related genes across cancers and their potential implications in osteosarcoma. | Sci Prog | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor Extracellular Vesicles lncOSLMT Drives Lung Inflammatory Premetastatic Niche Formation in Osteosarcoma via m6A-Dependent hnRNPA2B1/COX-2 Axis. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A triple-action PROTAC for wild-type p53 cancer therapy. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression. | J Transl Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Biological Activity of Biomarkers Associated With Metastasis in Osteosarcoma Cell Lines. | Cancer Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma. | Oncogene | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting IL-11R/EZH2 signaling axis as a therapeutic strategy for osteosarcoma lung metastases. | Discov Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Searching for novel MDM2/MDMX dual inhibitors through a drug repurposing approach. | J Enzyme Inhib Med Chem | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| FAM193A is a positive regulator of p53 activity. | Cell Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma. | EBioMedicine | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Podoplanin for the Treatment of Osteosarcoma. | Clin Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents. | Mol Cancer Ther | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1697/papers